First Manhattan’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

First Manhattan’s Portfolio SCPS Stock Details SCPS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,100	Closed	-$3K	–	1820
2022 Q3	$3K	Sell	13,100 -12,700	-49%	-$4.61K	﹤0.01%	1407
2022 Q2	$11K	Hold	25,800	–	–	﹤0.01%	1218
2022 Q1	$17K	Hold	25,800	–	–	﹤0.01%	1203
2021 Q4	$42K	Sell	25,800 -2,000	-7%	-$6.06K	﹤0.01%	1022
2021 Q3	$115K	Buy	27,800 +18,500	+199%	+$95.2K	﹤0.01%	834
2021 Q2	$66K	Sell	9,300 -1,000	-10%	-$7.12K	﹤0.01%	929
2021 Q1	$87K	Sell	10,300 -100	-1%	-$1.05K	﹤0.01%	851
2020 Q4	$154K	Buy	+10,400	New	+$184K	﹤0.01%	715

Other funds holding SCPS

MRCM

M&R Capital Management Summit, New Jersey $454M AUM 40.11% 1-Year Est. Return

First Manhattan's SCPS Position: Q4 2022 in Review

First Manhattan sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q4 2022, closing a stake of 13,100 shares — an estimated $3K sold.

First Manhattan first reported a position in SCPS in Q4 2020 and held it in 8 quarters. The position peaked at $154K in Q4 2020. 1 fund tracked by Wall St. Rank holds SCPS as of Q4 2022.

First Manhattan reported no remaining Scopus BioPharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
First Manhattan sold 13,100 Scopus BioPharma Inc. Common Stock shares in Q4 2022, an estimated $3K.
First Manhattan first reported a position in Scopus BioPharma Inc. Common Stock in Q4 2020 and held it in 8 quarters.
First Manhattan's Scopus BioPharma Inc. Common Stock position peaked at $154K in Q4 2020.
1 fund tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q4 2022.

Based on First Manhattan's 13F filing for Q4 2022, filed 14 Feb 2023.